Silencing of miR-34a using a miR-34a inhibitor was shown to prevent liver injury and improve hepatic steatosis through its target proteins, like PPARα and SIRT1, which can activate AMP-activated protein kinase in an animal model of NAFLD (50). This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.